Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2019

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-Outcomes
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Jun 2019 Results published in the Annals of Internal Medicine
    • 23 May 2019 Results assessing the effects of alirocumab on types of Myocardial Infarction published in the European Heart Journal
    • 23 May 2019 Results assessing the effects of alirocumab on death after index acute coronary syndrome (ACS) published in the Circulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top